<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40550096</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>25</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Voclosporin: A comprehensive review of its role as a novel calcineurin inhibitor in the management of systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>e42858</StartPage><MedlinePgn>e42858</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e42858</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000042858</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus is an autoimmune disease with diverse clinical manifestations, including lupus nephritis. Calcineurin inhibitors (CNIs) are a treatment option, but traditional CNIs have limitations. Voclosporin, a novel oral CNI, inhibits calcineurin to modulate T-cell activation and stabilize podocytes in lupus nephritis. This review assesses voclosporin's therapeutic potential in treating SLE (lupus nephritis), examining its mechanism of action, clinical efficacy, safety profile, and advantages over other CNIs. A broad search was conducted to identify studies published from 2009 to 2024 on voclosporin and other CNIs in lupus nephritis, using databases such as PUBMED, SCOPUS, Google Scholar and Cochrane Library. MeSH Keywords included "voclosporin," "lupus nephritis," "systemic lupus erythematosus," and "calcineurin inhibitors." Studies were included if they reported relevant clinical outcomes, evaluated voclosporin in lupus nephritis, or provided comparative data on voclosporin versus other CNIs, focusing on randomized controlled trials, systematic reviews, meta-analyses, retrospective studies and cohort studies. Voclosporin demonstrated higher renal response rates at 52 weeks than standard treatment alone (40.8% vs 22.5%). It has stable pharmacokinetics, reducing the need for individualized dose adjustments and frequent monitoring. Safety outcomes show a lower incidence of adverse effects like hypertension and hyperlipidemia compared to traditional CNIs. Voclosporin offers superior efficacy and safety compared to traditional CNIs for managing lupus nephritis, with predictable dosing and a favorable side effect profile. Continued research is needed to optimize voclosporin's use and support personalized medicine approaches.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ashinze</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Clinical Sciences, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>82 Division Medical Service Hospital, Enugu, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Research, Toufik's World Medical Association, Sumy, Ukraine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Lind League, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mafua</LastName><ForeName>Nelson</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Clinical Sciences, Madonna University, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Suvam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Health and Family Welfare, Burdwan Medical College and Hospital, Government of West Bengal, Kolkata, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obafemi</LastName><ForeName>Eniola</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Clinical Sciences, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eniola</LastName><ForeName>Akande</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Clinical Sciences, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emmanuel</LastName><ForeName>Egbunu</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Clinical Sciences, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Services, Federal Medical Centre, Niger, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edache</LastName><ForeName>Akogwu Ocholi</ForeName><Initials>AO</Initials><AffiliationInfo><Affiliation>Faculty of Clinical Sciences, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozioma</LastName><ForeName>Chukwu Bethrand</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Faculty of Clinical Sciences, University of Ilorin, Ilorin, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wireko</LastName><ForeName>Andrew Awuah</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Division of Research, Toufik's World Medical Association, Sumy, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul-Rahman</LastName><ForeName>Toufik</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0153-287</Identifier><AffiliationInfo><Affiliation>Division of Research, Toufik's World Medical Association, Sumy, Ukraine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065095">Calcineurin Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber><NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance></Chemical><Chemical><RegistryNumber>2PN063X6B1</RegistryNumber><NameOfSubstance UI="C484071">voclosporin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065095" MajorTopicYN="Y">Calcineurin Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016572" MajorTopicYN="Y">Cyclosporine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="Y">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">calcineurin inhibitors</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">voclosporin</Keyword></KeywordList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>23</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40550096</ArticleId><ArticleId IdType="pmc">PMC12187296</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000042858</ArticleId><ArticleId IdType="pii">00005792-202506200-00082</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kayser C, Dutra LA, Reis-Neto ETD, De Moura Castro CH, Fritzler MJ, Andrade LEC. The role of autoantibody testing in modern personalized medicine. Clin Rev Allergy Immunol. 2022;63:251&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">35244870</ArticleId></ArticleIdList></Reference><Reference><Citation>Rios SM, Martinez RR, Ramirez GME, Medina YF. Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report. Modern Rheumatol Case Rep. 2022;7:43&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903504</ArticleId><ArticleId IdType="pubmed">35246682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergianaki I, Fanouriakis A, Repa A, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis. 2017;76:1992&#x2013;2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">28780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers EC, Marder W, Cagnoli P, et al. Population&#x2010;based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program. Arthritis Rheumatol. 2014;66:369&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198147</ArticleId><ArticleId IdType="pubmed">24504809</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Hahn BH, Dubois EL, Isenberg D. Dubois&#x2019; Lupus erythematosus and related syndromes. In: Elsevier eBooks. 2013. 10.1016/c2010-0-66018-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/c2010-0-66018-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Justiz Vaillant AA, Goyal A, Varacallo M. Systemic Lupus Erythematosus. StatPearls; 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">30571026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli S, Lonati PA, Gerosa M, Caporali R, Cimaz R, Chighizola CB. Beyond systemic lupus erythematosus and anti-phospholipid syndrome: the relevance of complement from pathogenesis to pregnancy outcome in other systemic rheumatologic diseases. Front Pharmacol. 2022;13:841785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8886148</ArticleId><ArticleId IdType="pubmed">35242041</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SK, Costenbader KH. Prognosis and mortality of SLE. In: Elsevier eBooks. 2019:770&#x2013;81.</Citation></Reference><Reference><Citation>Wang Z, Li M, Ye Z, et al. Long-term outcomes of patients with systemic lupus erythematosus: a multicenter cohort study from CSTAR registry. Rheumatol Immunol Res. 2021;2:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9524789</ArticleId><ArticleId IdType="pubmed">36465068</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:73736&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Ugarte A, Pijoan JI. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol. 2020;32:56561&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">29870497</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzm&#xe1;n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:72721&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2017;376:1246&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2012;23:1401&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678035</ArticleId><ArticleId IdType="pubmed">19369404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437757</ArticleId><ArticleId IdType="pubmed">22556106</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman CH, Hiraki LT, Winkelmayer WC, et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2020;67:1577&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4446132</ArticleId><ArticleId IdType="pubmed">25772621</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Mathian A, Adoue D, et al. Enteric dysbiosis in systemic lupus erythematosus: a potentially new target for disease management. Lupus. 2019;28:713&#x2013;23.</Citation></Reference><Reference><Citation>Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2016;30:386&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24238690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Pons-Estel GJ, Vila LM, et al. ; Grupo Latino Americano de Estudio de Lupus (GLADEL). Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. Lupus Sci Med. 2018;5:e000234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560976</ArticleId><ArticleId IdType="pubmed">31245057</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheumatic Dis. 2018;77:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952401</ArticleId><ArticleId IdType="pubmed">19892750</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz DE, Kirschner K, Demirci H, Himmerkus N, Bachmann S, Mutig K. Immunosuppressive calcineurin inhibitor cyclosporine A induces proapoptotic endoplasmic reticulum stress in renal tubular cells. J Biol Chem. 2022;298:101589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8857494</ArticleId><ArticleId IdType="pubmed">35033536</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">1374612</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia JC. Ron Shapiro, in Kidney Transplantation&#x2013;Principles and Practice. Seventh Edition; 2014</Citation></Reference><Reference><Citation>Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE. Tacrolimus (FK 506) &#x2013; a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol. 1992;128:781&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208344</ArticleId><ArticleId IdType="pubmed">1376102</ArticleId></ArticleIdList></Reference><Reference><Citation>Liossis SN, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest. 1998;101:1448&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508723</ArticleId><ArticleId IdType="pubmed">9525988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75:30&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25550339</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey FJ. [Cyclosporin in autoimmune diseases]. Schweiz Med Wochenschr. 1990;120:772&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2190313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ab&#x119;d&#x17a; N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. Postepy Dermatol Alergol. 2019;36:752&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986278</ArticleId><ArticleId IdType="pubmed">31998006</ArticleId></ArticleIdList></Reference><Reference><Citation>Song YH, Cai GY, Xiao YF, et al. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. BMC Nephrol. 2017;18:61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5307812</ArticleId><ArticleId IdType="pubmed">28193247</ArticleId></ArticleIdList></Reference><Reference><Citation>Safarini OA, Keshavamurthy C, Patel P. Calcineurin inhibitors. [Updated 2023 Nov 12]. In: StatPearls. StatPearls Publishing; 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">32644421</ArticleId></ArticleIdList></Reference><Reference><Citation>Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity-what the FK? Adv Chronic Kidney Dis. 2020;27:56&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080294</ArticleId><ArticleId IdType="pubmed">32147003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez Nieto M, 1, Jayne DR. Con: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant. 2016;31:1567&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">27591328</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gelder T, Lerma E, Engelke K, Huizinga RB. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. Exp Rev Clin Pharmacol. 2022;15:515&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">35763288</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah VR, Bankole A. Voclosporin. [Updated 2023 Jun 15]. In: StatPearls. StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK592419/.</Citation><ArticleIdList><ArticleId IdType="pubmed">37276315</ArticleId></ArticleIdList></Reference><Reference><Citation>David W, Vincenti F. Chapter 95 &#x2013; Novel immunosuppressive drugs. In: Busuttil RW, Klintmalm GBG, eds. Transplantation of the Liver (Third Edition), W.B. Saunders; 2015:1332&#x2013;42. 10.1016/B978-1-4557-0268-8.000955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-1-4557-0268-8.000955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kale A, Shelke V, Lei Y, Gaikwad AB, Anders H-J. &#x201c;Voclosporin: unique chemistry, pharmacology and toxicity profile, and possible options for implementation into the management of lupus nephritis&#x201d;. Cells. 2023;12:2440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10605893</ArticleId><ArticleId IdType="pubmed">37887284</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriens C, Polyakova S, Adzerikho I, Randhawa S, Solomons N. Op0277Aurora phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). Ann Rheum Dis. 2020;79:172&#x2013;3.</Citation></Reference><Reference><Citation>Adaku C, Ume JMP, Kemp MG, Williams CR. Calcineurin inhibitor (CNI)-associated skin cancers: new insights on exploring mechanisms by which CNIs downregulate DNA repair machinery. Wiley Online Library. 2020;1:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11042075</ArticleId><ArticleId IdType="pubmed">32786098</ArticleId></ArticleIdList></Reference><Reference><Citation>Menn-Josephy H, Hodge LS, Birardi V, Leher H. Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria. Clin J Am Soc Nephrol. 2023;19:309&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10937024</ArticleId><ArticleId IdType="pubmed">38110196</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Solomons N, Pendergraft WF, III, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95:219&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30420324</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp K, Pariser D, Catlin M, et al. A phase 2b randomized study of voclosporin (VCS) ointment in patients with stable plaque psoriasis. J Am Acad Dermatol. 2020;82:129&#x2013;36.</Citation></Reference><Reference><Citation>Sin FE, Isenberg D. An evaluation of voclosporin for the treatment of lupus nephritis. Expert Opin Pharmacother. 2018;19:1613&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207816</ArticleId></ArticleIdList></Reference><Reference><Citation>Mej&#xed;a-Vilet JM, Romero-D&#xed;az J. Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis. Expert Rev Clin Immunol. 2021;17:937&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">34392746</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo A. Voclosporin: first approval. Drugs. 2021;81:605&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010786</ArticleId><ArticleId IdType="pubmed">33788181</ArticleId></ArticleIdList></Reference><Reference><Citation>Businesswire. FDA approves Aurinia Pharmaceuticals&#x2019; Lupkynis&#x2122; (voclosporin) for adult patients with active lupus nephritis [media release].
2021. www.businesswire.com.</Citation></Reference><Reference><Citation>Gelder T, Robert H, Laura L, Neil S. Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. Nephrol Dial Trans. 2021;3:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035351</ArticleId><ArticleId IdType="pubmed">33527141</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Ponticelli C. AURORA 1 reports efficacy of voclosporin in lupus nephritis. Nat Rev Nephrol. 2021;17:637&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34211153</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriens C, Onno Teng YK, Ginzler EM, et al. Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis. Arthritis Care Res. 2023;75:1399&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">36039949</ArticleId></ArticleIdList></Reference><Reference><Citation>Liossis SN, Staveri C. What&#x2019;s new in the treatment of systemic lupus erythematosus. Front Med. 2021;8:655100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7973110</ArticleId><ArticleId IdType="pubmed">33748165</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Fernandez-Ruiz R, Blazer A, Niewold TB. Advances in the management of systemic lupus erythematosus. BMJ. 2023;383:e073980.</Citation><ArticleIdList><ArticleId IdType="pubmed">37884289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>